France · Delayed Price · Currency is EUR ABIONYX Pharma Statistics
Total Valuation
ABIONYX Pharma has a market cap or net worth of EUR 78.35 million. The enterprise value is 78.63 million.
| Market Cap | 78.35M |
| Enterprise Value | 78.63M |
Important Dates
The next confirmed earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABIONYX Pharma has 35.29 million shares outstanding. The number of shares has increased by 3.73% in one year.
| Current Share Class | 35.29M |
| Shares Outstanding | 35.29M |
| Shares Change (YoY) | +3.73% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 35.78% |
| Owned by Institutions (%) | 4.30% |
| Float | 19.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.28 |
| PB Ratio | 17.36 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 19.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.84.
| Current Ratio | 1.06 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.20 |
| Interest Coverage | -65.15 |
Financial Efficiency
Return on equity (ROE) is -92.29% and return on invested capital (ROIC) is -115.47%.
| Return on Equity (ROE) | -92.29% |
| Return on Assets (ROA) | -25.97% |
| Return on Invested Capital (ROIC) | -115.47% |
| Return on Capital Employed (ROCE) | -69.64% |
| Weighted Average Cost of Capital (WACC) | 6.73% |
| Revenue Per Employee | 82,918 |
| Profits Per Employee | -113,265 |
| Employee Count | 49 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 15.15 |
Taxes
In the past 12 months, ABIONYX Pharma has paid 9,000 in taxes.
| Income Tax | 9,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +81.97% in the last 52 weeks. The beta is 0.49, so ABIONYX Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +81.97% |
| 50-Day Moving Average | 3.22 |
| 200-Day Moving Average | 3.57 |
| Relative Strength Index (RSI) | 19.82 |
| Average Volume (20 Days) | 215,326 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ABIONYX Pharma had revenue of EUR 4.06 million and -5.55 million in losses. Loss per share was -0.16.
| Revenue | 4.06M |
| Gross Profit | 534,000 |
| Operating Income | -5.54M |
| Pretax Income | -5.54M |
| Net Income | -5.55M |
| EBITDA | -5.42M |
| EBIT | -5.54M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 3.52 million in cash and 3.81 million in debt, with a net cash position of -284,000 or -0.01 per share.
| Cash & Cash Equivalents | 3.52M |
| Total Debt | 3.81M |
| Net Cash | -284,000 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | 4.51M |
| Book Value Per Share | 0.13 |
| Working Capital | 304,000 |
Cash Flow
In the last 12 months, operating cash flow was -2.93 million and capital expenditures -242,000, giving a free cash flow of -3.18 million.
| Operating Cash Flow | -2.93M |
| Capital Expenditures | -242,000 |
| Depreciation & Amortization | 115,000 |
| Net Borrowing | -429,000 |
| Free Cash Flow | -3.18M |
| FCF Per Share | -0.09 |
Margins
Gross margin is 13.14%, with operating and profit margins of -136.30% and -136.60%.
| Gross Margin | 13.14% |
| Operating Margin | -136.30% |
| Pretax Margin | -136.38% |
| Profit Margin | -136.60% |
| EBITDA Margin | -133.47% |
| EBIT Margin | -136.30% |
| FCF Margin | n/a |
Dividends & Yields
ABIONYX Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.73% |
| Shareholder Yield | -3.73% |
| Earnings Yield | -7.08% |
| FCF Yield | -4.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for ABIONYX Pharma is 10.50, which is 372.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 10.50 |
| Price Target Difference | 372.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 110.06% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ABIONYX Pharma has an Altman Z-Score of 3.62 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.62 |
| Piotroski F-Score | 3 |